Astra Sacks Lars Bildman

30 June 1996

Astra USA, the US unit of Swedish drug company Astra, has terminated the employment of Lars Bildman as president and chief executive of the company. He was suspended on April 28 pending results of an investigation into allegations of improprieties within the company that occurred during his tenure (Marketletters passim). Mr Bildman chose not to cooperate with the investigation, according to the company.

"Our investigation uncovered management behavior under Mr Bildman that is unacceptable to Astra," said vice president of Astra AB, C G Johansson, who headed the investigating committee.

The investigation uncovered evidence of "inappropriate behavior at company functions" and misuse of company funds, among other things. The firm is cooperating with the US Equal Employment Opportunity Commission in its investigation of allegations of sexual harassment.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight